4A3380).
Introduction
Highly specific proteolysis at distinct sites identified by paired basic amino acids is an important requirement for the processing of a large number of protein precursors (1,2). These proproteins include virtually all the neuropeptide and peptide hormones, as well as a large and diverse family of membrane and viral glycoproteins, growth factors, hormone receptors, and plasma proteins (3-8).
O n synthesis of a pre-proform of a secretory protein, an initial cleavage occurs in the endoplasmic reticulum to remove the amino terminal signal peptide, and the proprotein is further processed through the Golgi and secretory granules to attain the mature form ready for secretion (1, 9) . Structural studies have shown that although the proteins have different primary sequences, they share common motifs for processing (1-3,643). Endoproteolytic cleavages usually occur on the carboxyl side of paired basic residues (Lys-Arg or Arg-Arg and less frequently Arg-Lys and Lys-Lys) and are followed by the action of carboxypeptidase E, which removes the basic amino acids from the new carboxyl terminus (10).
of PC1 and PC2 with proinsulin in islet P-cellS indicates that Despite intensive efforts, it is only recently that six prohormone and proprotein convertases (conversion endoproteases) that carry out some of these cleavages have been identified and molecularly characterized (11-20). These were called furin (ll), PC1 (12,13; also called PC3 in 14), PC2 (13J5), PACE4 (16). PC4 (17,18), and PC5 (19; also called PC6 in 20). Tissue and cellular expression analyses demonstrated that furin is ubiquitously expressed in all tissues and cells (21,22), whereas PACE4 (16) and PC5 (19, 20) are widely distributed in both endocrine and non-endocrine cells. PC4 is synthesized in testicular germ cells (17, 18) and in ovaries (18). Finally, PC1 and PC2 are the only convertases that are primarily expressed in endocrine and neural cells (7,12-15,22). By heterologous gene transfer experiments, PC2 and/or PC1 were shown to be capable of cleaving selectively at specific pairs of basic residues sites in proopiomelanocortin (POMC) (4,23), proinsulin (5,24,25), proenkephalin (26), human prorenin (27) , prosomatostatin (28), and proglucagon (29) .
The process of proinsulin secretion has been extensively investigated through biochemical and morphological approaches, and the main events from synthesis of the pre-proinsulin to the secretion of the mature insulin, its transport to blood circulation, and binding to specific receptors have been identified (30) (31) (32) (33) (34) . Along the maturation process of proinsulin two convertases have been thus far recognized. These enzymes are identical to the previously designated Type I (PC1) and Type I1 (PC2) proteases (24,25), are Ca2+-MALIDE, SEIDAH, CWTIEN, BENDAYAN dependent, display a pH optimum of 5.5-6.0, and appear to be selective for cleavage at the B-chain C-peptide (Arg-Arg) and C-peptide A-chain (Lys-Arg) processing sites within proinsulin, respectively.
The identification and isolation of PC2 from human (15) and mouse ( 1 2~3 ) insulinomas, the finding by Northem blot analysis that PC1 and PC2 are expressed in both insulinoma tissue and isolated islets of Langerhans, as well as their recent immunohistochemical localization in pancreatic tissue (5), led us to investigate by an ultrastructural approach the role of these enzymes in the proteolytic maturation of proinsulin.
The present study was conducted to identlfy the subcellular prohormone processing compartments within rat insulin-secreting cells, in relation to the prohormone convertases and proinsulin immunolabeling, using an immunocytochemical technique at the electron microscopic level. We attempted to map the distribution of granules containing the enzymes and the hormone precursors along the secretory pathway.
Materials and Methods
Tissue Samples. Pancreatic tissue from five normal Sprague-Dawley rats was fixed by immersion with 1% glutaraldehyde in 0.1 mollliter phosphate buffer (pH 7.4) for 2 hr at room temperature (RT), dehydrated in graded methanol, and embedded in either Lowicryl K4M at -2O'C, as previously described (35), or in Unicryl (British BioCell; Cardiff, UK) at -20°C (36). Thin sections were cut, mounted on nickel grids with or without Parlodion coating, and processed for post-embedding colloidal gold immunocytochemistry.
Antibodies. In the present study we used several rabbit polyclonal antibodies to localize the prohormone convertases PC1 and PC2 and a monoclonal antibody to proinsulin. For PC1 two antibodies were employed: (a) Ab C-mPC1, directed against the carboxyl terminal (C-terminal) segment 629-726 of mouse PC1 (mPCl), and (b) Ab N-mPC1, directed against the amino terminal (N-terminal) segment 84-98+Tyr of mouse PC1 (27, 37) . The N-terminal-directed antibody recognizes the 87, 84 and 66 KD forms of PC1, whereas the C-terminal directed antibody recognizes only the 87 KD proPC1 and the 84 KD form of PC1 (37, 38) . For the double labeling experiments a mixture of both antibodies directed to PC1 was applied. For PC2 we utilized two C-terminal-directed antibodies: (a) Ab C-mPC2, directed against the C-terminal segment 529-637 of mouse PC2 (mPC2) (9,10), and (b) Ab C KLH-mPC2 directed against the last 10 amino acids of the C-terminal tail of PC2 (kindly provided by Dr. R.H. Angeletti, Albert Einstein College of Medicine, New York). The specificity of these antibodies was previously well demonstrated by immunochemical techniques (7, 27, 37, 39, 40) .
The human proinsulin-specific monoclonal antibody (Novo Nordisk BioLabs; Bagsvaerd, Denmark) used in our double-labeling experiments has been previously characterized (41). It recognizes an epitope at the B-Cchain junction around the dibasic processing site (Arghrg) in position 31-32 of human proinsulin. Crossreactivity with rat proinsulin was already established (31).
Immunoelectron Microscopy. Before performing any immunolabeling, the polyclonal antibodies were absorbed by incubation for 16 hr at 4'C with glutathione-S-transferase (100 pl antiseruml80 pg protein) to block any antibody directed against the fusion partner.
For immunolabeling, the tissue sections were first transferred for 30 min on a drop of 0.15 mollliter PBS, pH 7.2, containing 1 I ovalbumin and then incubated with the specific antibody brought to the appropriate dilution: Ab C-mPC1, 1:150; Ab N-mPC1, 1:lOO; Ab C-mPC2, 1:500; or the monoclonal anti-proinsulin antibody, 1:10, overnight at 4'C. The sections were further rinsed with PBS to remove the unbound immunoglobulins and then incubated for 30 min at RT with the protein A-gold complex prepared with lo-nm gold particles (ODl>o = 0.5) as described previously (42) . The grids were then washed with PBS and distilled water, dried, and stained with uranyl acetate before examination.
The specificity of the labeling was assessed through a number of control experiments. Several adsorptions were performed as follows. Tissue sections were incubated: (a) with the specific Ab C-mPC1 antibody pre-adsorbed either with C-terminal peptide of mPCl(l.5 mglml) or with C-termind fusion protein of mPCl(0.4 mglml); (b) with the specific Ab N-mPC1 antibody pre-adsorbed either with N-terminal peptide of mPCl(2 mglml), or with N-terminal fusion protein of mPCl (0.5 mglml); or (c) with the specific Ab C-mPC2 antibody pre-adsorbed either with C-terminal peptide of mPC2 (1.25 mglml), or with C-terminal fusion protein of mPC2 (0.28 mglml). Other controls were performed by incubating the tissue sections with a non-related rabbit antiserum instead of the specific antibody or directly with protein A-gold without prior exposure to any antibody.
To assess co-localization, two approaches were used: serial sections and double-labeling protocols. Consecutive serial sections were cut and were subsequently immunolabeled with the above-mentioned antibodies in conjunction with protein A-gold complexes.
For double-immunogold labeling, both sides of the tissue sections were used, according to Bendayan (43) . Combinations of anti-PCllanti-PC2, anti-PCllproinsulin, and anti-PC2lproinsulin antibodies were used on different faces of the grids in conjunction with protein A-gold complexes formed by 5-, lo-, or 15-nm gold particles.
Immunogold Quantification. Quantitative evaluations of the labeling present over the RER, Golgi area, immature, and mature secretory granules were carried out according to previously described protocols (32). Forty micrographs of at least 15 different pancreatic @cells from the five animals were recorded and enlarged to a final magnification of x 40,000. The area of cellular compartments of interest for the present investigation was evaluated by direct planimetry using the Videoplan-2 system (Carl Zeiss; Don Mills, Ontario, Canada). The number of gold particles present in those areas was directly counted and the density of labeling was expressed as number of gold particles per square micrometer. Student's t-test analysis was applied for statistical evaluations.
Results
Using immunohistochemistry in mouse pancreas (40) and immunogold labeling in rat pancreas (this work), PC2-like immunoreactivity was detected in the islets of Langerhans within insulin, glucagon, and somatostatin cells. Similarly, PC1-like immunoreactivity was detected in the 0-cells of the rat pancreas. No immunostaining was observed within the exocrine pancreas. The present study was focused on immunolocalization at the electron microscopic level of both PC1 and PC2 in insulin-secreting P-cells. Using protein A-gold in conjunction with specific antibodies to reveal different antigenic sites of PC1 and PC2, the labeling displayed a pattern that follows the regulated secretory pathway. The gold particles were distributed over the RER, Golgi area, and secretory granules. Using several antibodies directed against both prohormone convertases, the labeling was found to be mainly associated with a particular population of immature secretory granules characterized by a coated limiting membrane (Figures la and 2a ). The non-coated secretory granules, resulting from maturation of the coated ones, displayed lower PC1 and PC2 immunoreactivity and the gold particles deco- Ab N-mPC1, antibodies directed to the N-terminal side of mouse PCl; Ab C-mPC1, antibodies directed to the C-terminal side of mouse PC1; Ab C-mPC2, antibodies directed to the C-terminal side of mouse PC2; Ab C KLH-mPC2. antibodies directed to the Germinal side of mouse PC2. Figure 3 . PC2 immunolabeling revealed by the C KLH-mPC2 antibody shows gold particles distributed with the same intensity over many secretory granules, either immature ones with tightly fitting cores (is) or at the periphery of the mature ones (mg). Multigranular bodies (mgb) are also labeled; G, Golgi apparatus; M, mitochondrion. Original magnification: x 32,000. Bar = 0.25 pm. rated mainly the periphery of the dense core of the granule (Figures  1b and 2b) . In general, the labeling intensities obtained for PC1 and PC2 in cellular compartments increased gradually along the secretory pathway to reach a peak over the immature granules, and then decreased (Eble 1). In addition, several multigranular bodies (crinophagic bodies) containing granule core-like material were also immunolabeled ( Figure 3) .
Labeling for PC2 with the second antibody recognizing the C-terminal 10 amino acids of PC2 showed little variation among the granules. The labeling was distributed with similar intensity over both immature and mature granules. Several multigranular bodies were also labeled ( Figure 3 ).
Quantitative analysis of the relative distribution of gold particles among the different cellular compartments revealed a similar pattern for both enzymes. In fact, the labeling of immature granules was twofold greater than that of the mature ones and fourto fivefold greater than that of the RER and the Golgi complex (Eble 1 ; Figures 1-3) .
The immunolabeling was almost completely abolished by preadsorption of the antibodies with their corresponding peptides or fusion proteins, confirming the high specificity of the results (Figures 4 and 5 ; Eble 2) .
Regarding the subcellular localization of proinsulin, specific labeling was found in the RER, Golgi apparatus, and in a population of immature secretory granules located mainly in the Golgi area. The mature granules and the multigranular bodies were not labeled ( Figure 6 ).
Double-immunogold labeling with quantitative analysis indicated that PC1 co-localizes with PC2 in the majority (86%) of the immature granules (Figure 7a ).
Double labeling with anti-PC1 or anti-PC2 and anti-proinsulin antibodies revealed that the majority of the proinsulin-rich granules also exhibited PC1 and PC2 immunoreactivity (Figures 7b-7e ).
Quantitative evaluation showed expression of PC1 in 63% of proinsulin-labeled granules and expression of PC2 in 60% of proinsulin-labeled granules (Figures 7b and 7e) . In both cases, 20% of the negative proinsulin granules (mature granules) demonstrated labeling for the respective prohormone convertases (Figures 7c and  7e) . When anti-PC1 and anti-PC2 antibodies were pooled and used in combination with anti-proinsulin antibodies in double-labeling experiments, co-expression of prohormone convertases occurred in 75% of proinsulin-labeled granules. These results indicate the presence of either or both convertases in the proinsulin granule, which leads to partial overlap between their distribution in the large majority of the immature granules. However, it also reveals that 2 5 % of the proinsulin-rich granules are devoid of PC1 or PC2 immunoreactivity.
Although the apparent lack of the distribution of the prohormone convertases in some proinsulin-immunoreactive granules probably arises from differential detectability or accessibility of their epitopes, we cannot completely rule out the involvement of other processing enzyme(s).
The co-localization of proinsulin and PC1 and PC2 was also conf m e d when consecutive serial sections were labeled with the different antibodies; both proinsulin and the prohormone convertase were usually found in the same immature secretory granules.
Discussion
Using a high-resolution immunocytochemical approach at the electron microscopic level, we have addressed the following question: is there one definite morphological compartment in the P-cell responsible for the conversion of proinsulin?
We present here the co-localization of proinsulin and prohormone convertases in rat pancreatic P-cells providing morphological evidence for a subcellular site of conversion of proinsulin into the mature hormone. Furthermore, we provide evidence that PC1 and PC2 are co-localized within the same granules. It was previously shown (31) that proinsulin-immunoreactive sites are associated with the coated secretory granules. In addition, it was also demonstrated that the conversion of the insulin occurs coordinately with acidification of maturing secretory granules (44,45).
As described in this study, the labeling densities of both PC1 and PC2 follow a pattern of gradual increase along the secretory pathway, and the values are higher in the proinsulin-rich coated immature granules.
Biosynthetic analysis of the processing of pro-PC1 (87 KD) and pro-PC2 (75 KD) into PC1 (84 KD) and PC2 (65 KD) demonstrated that the zymogen activation of pro-PC1 is very rapid and occurs in the RER (27, 37, 38) , whereas that of pro-PC2 occurs in the E N and continues in the secretory granules (37,46). Furthermore, unlike PC2, which remains as the 65 KD form (37,47), PCI (84 KD) is further converted within granules into a C-terminally truncated form of 66 KD (38). However, it is not clear whether the processing of pro-PC1 into the 84 KD and 66 KD forms occurs by an autocatalytic process (48, 49) . Similarly, pro-PC2 conversion into PC2 was suggested to occur by an autocatalytic intermolecular mechanism (50). In view of the fast conversion of pro-PC1 into PC1 within the RER (38), it is expected that the C-terminally directed PC1 antibody recognizes predominantly the 84 KD form and the presum- ably released 18 KD C-terminal fragment after conversion of the 84 KD into the 66 KD form. However, the fate of the 18 KD peptide has not yet been explained. In addition, the N-terminal antibody recognizes both the 66 KD and the 84 KD forms of PCl. Although we were not able to distinguish major differences in the labeling pattern obtained with these antibodies, a shift of the labeling density to the initial secretory compartments was observed when the C-terminal-directed antibody was employed. This antibody yielded a higher density over the RER and Golgi area relative to the N-terminal-directed antibody. With this antibody, 35% of the total intracellular labeling was over the RER and Golgi area, compared with 20% when the N-terminal antibody was used. This change in the labeling distribution might reflect the expression of an early processing of pro-PC1 to generate the 84 KD active enzyme in the RER compartment, compared with the late processing of the 84 KD into the 66 KD form.
A distinct observation was made with the antibodies directed against the last 10 amino acids of the C-terminal tail of PC2, which showed no variation in labeling density between the immature and mature secretory granules. These results, which indicate the presence of this C-terminal epitope in both immature and mature granules, are in agreement with the observation that PC2 is not processed to a shorter form than the mature 65 KD one (37.48). Regardless of the antibodies used, the co-expression of proinsulin and PC1 or PC2 was found to occur in 63% and 60% of the immature granules, respectively. When both anti-PC1 and -PC2 antibodies were pooled and used in combination with anti-proinsulin antibodies, the co-expression reached 75% of the proinsulin-labeled granules. It therefore appears that some proinsulin-rich granules do not display convertase immunoreactivity. This result might raise some concern regarding the consequence of no processing of proinsulin and is difficult to rationalize it with the levels of proinsulin vs insulin secreted by P-cells. Although these data suggest the existence of proinsulin-rich granules without prohormone convertase PC1 and PC2 immunoreactivity, we cannot conclude that they are completely devoid of any convertase. We have first to consider that, with im- munocytochemical approaches, there are technical limits in the detectability of an antigen (35) . Under these conditions, the less than complete co-distribution of proinsulin and processing enzymes may reflect differential epitope accessibility. It also could be due to low levels of PC1 and PC2, which may fall below the threshold of our detection. Alternatively, it could also indicate that other as yet undefined convertase(s) [e.g., PACE4 (16) and/or PC51 may be present in these granules (19, 20) . Conversely, we observed that some mature granules displaying no proinsulin immunoreactivity still contain prohormone convertases. This indicates that enzyme immunoreactivities remain in the granule on completion of the conversion, the convertases probably being secreted along with insulin. In fact, our data are consistent with previous biosynthetic labeling experiments (5132) demonstrating that the prohormone convertases and the prohormone reach the secretory granules simultaneously. Along with insulin, the convertases are released into the extracellular medium, their secretion being stimulated by secretagogues (38.53).
The presence of immunoreactivity for the convertases, C-peptide, and insulin (32). but not for proinsulin, in multigranular bodies also indicates that as an alternative to secretion, some of the prohormone convertases might be routed to lysosomes, where they would undergo intracellular degradation by crinophagy. The fact that proinsulin immunoreactivity was not found within the multigranular bodies supports the concept that the crinophagic phenomenon occurs only on maturation of insulin.
The double-labeling experiments demonstrated that the two prohormone convertases PCI and PC2 co-localize in insulin immature granules, which might indicate that they would be able to cleave the proinsulin simultaneously. However, there is experimental evidence for sequential processing mechanisms for prohormones (54). For example, POMC is first cleaved into b-LPH by PCI, which is then followed by the action of PC2 to cleave b-LPH into b-endorphin (4), a phenomenon that was explained by the order of zymogen activation of the convertases. A similar order of cleavage was also reported for proinsulin (5, 24, 25, 53) . in which PC1 would act first to cleave it at the Arg3l-Arg32 . C site (BIC junction) followed by cleavage by PC2 at the Lys64-Arg6~ J-bond (CIA junction), thereby generating insulin and C-peptide. Accordingly, the conversion of proinsulin to insulin is a multistep process involving endoproteolytic cleavage at two distinct sites in the precursor molecule (55-59). The key endopeptidase in proinsulin conversion mechanism seems to be PC1, which preferentially initiates this process (55.59). Furthermore, the biosynthesis of PC1 but not of PC2 is coordinately stimulated by glucose in a manner similar to that of proinsulin (60,61).
The removal of Arg31-Arg32 residues during a partial conversion by PC1 abolishes immunoreactivity to our anti-proinsulin monoclonal antibody (which can recognize only proinsulin but not the conversion intermediates), and hence enabled us to follow only the early events of this sequential process. Furthermore, since PC2 acts late in the processing reaction at a time when most of the proinsulin is converted to Des-Argjl-Argjz proinsulin, this may explain the observed lower levels of co-distribution of proinsulin and PC2.
Our data showing that the two prohormone convertases and the proinsulin co-distributed into the same subpopulation of immature granules provide morphological support for their role in the correct processing of proinsulin in rat insulin-secreting cells. Future studies should address the question of whether PC1 and PC2 are by themselves sufficient to explain all the processing intermediates found in the P-cells and which enzyme(s) co-localizes with proinsulin in those granules devoid of or having low levels of PC1 and PC2.
